If you’ve been using a GLP-1 such as semaglutide, then you’ve likely experienced the powerful effects of this weight loss ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Semaglutide 7.2 mg had a safety profile consistent with other GLP-1 receptor agonists ... More detailed results from the STEP UP trial are expected to be presented at a scientific conference ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...

consistent with the GLP-1 receptor agonist class. The results from the second semaglutide 7.2 mg phase 3 trial, STEP UP T2D, in adults with type 2 diabetes and obesity are expected within the next ...